In the current study, we tested the hypothesis that an in vivo immunomodulatory approach using IL-21 given at the time of immunization would augment the antibody response to flu vaccination in an aging and SIV-infection/ART-treated NHP model. The gene discussed is IL21; the disease is heterotaxy, visceral, 5, autosomal.